EUVIMEDEUVIMED entdecken
Crossref

Thyroxine Treatment of Adult RTHα Patients: Safety, Efficacy, and Metabolomic Changes

Alexander Bauer Westbye iD, Louise Koren Dahll, May Kristin Bredahl, Per Medbøe Thorsby, Sara Salehi Hammerstad

Thyroid® · 11.06.2026

DOI: 10.1177/10507256261460201 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Thyroid®, online erschienen am 11.06.2026. Verfasst von Alexander Bauer Westbye und 4 weiteren Autor:innen. Beteiligte Einrichtung: Hormone Laboratory, Department of Medical Biochemistry, Oslo University Hospital, Aker, Oslo, Norway. Hauptthemen laut MEDLINE: Thyroxine, Thyroid Hormone Resistance Syndrome, Hypothyroidism. Die Arbeit nennt 26 Literaturangaben. Gefördert von: Stoffskifteforbundet.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Resistance to thyroid hormone alpha (RTHα) is a rare genetic disorder with symptoms of hypothyroidism, but normal or close-to-normal thyroid function tests. Treatment with levothyroxine (L-T4) may be beneficial. This study investigated the efficacy, safety and biochemical changes of high-dose L-T4 and liothyronine (L-T3) treatment.

Methods

Four RTHα (Ala263Val) patients were treated with L-T4 (1.75 µg/kg) in a pilot open-label study and monitored for three years. Quality of life (QoL) was assessed using ThyPro. Analysis of auxiological- and biochemical-parameters, bone mineral density (BMD) and exploratory metabolomics was performed. A partial replacement of L-T4 with L-T3 was attempted.

Results

Treatment with L-T4 increased FT4, FT3, and rT3 to supraphysiological concentrations (relative to reference intervals) and suppressed thyroid-stimulating hormone with no adverse effects. Heart rate, bone markers, and sex hormone-binding globulin transiently increased. Several classes of lipids were reduced. BMD appeared unaltered. Patients reported improved QoL. One patient presented a short non-sustained ventricular tachycardia on L-T3 + L-T4.

Conclusions

L-T4 treatment of adult RTHα patients was safe and improved QoL in adherent patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ThyroxineThyroid Hormone Resistance SyndromeHypothyroidismHumansFemaleAdultMaleBone DensityMiddle AgedQuality of LifeMetabolomicsPilot ProjectsTriiodothyronineTreatment Outcome

Stichwörter der Autor:innen

RTHαTHRAhypothyroidismthyroid hormone receptorthyroid resistance

Substanzen

ThyroxineTriiodothyronine

Autor:innen und Institutionen

  • Hormone Laboratory, Department of Medical Biochemistry, Oslo University Hospital, Aker, Oslo, Norway.
  • Endocrinology and Metabolism Research Group, Oslo University Hospital, Aker, Oslo, Norway.
  • Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway.
  • Department of Endocrinology, Morbid Obesity and Preventive Medicine, Oslo University Hospital, Oslo, Norway.

ORCID-Profile: Alexander Bauer Westbye

Förderung

  • Stoffskifteforbundet

Zitieren

APA

Westbye, A. B., Dahll, L. K., Bredahl, M. K., Thorsby, P. M., & Hammerstad, S. S. (2026). Thyroxine Treatment of Adult RTHα Patients: Safety, Efficacy, and Metabolomic Changes. Thyroid®. https://doi.org/10.1177/10507256261460201

Vancouver

Westbye AB, Dahll LK, Bredahl MK, Thorsby PM, Hammerstad SS. Thyroxine Treatment of Adult RTHα Patients: Safety, Efficacy, and Metabolomic Changes. Thyroid®. 2026. doi:10.1177/10507256261460201

BibTeX
@article{Westbye2026,
  author = {Westbye, Alexander Bauer and Dahll, Louise Koren and Bredahl, May Kristin and Thorsby, Per Medbøe and Hammerstad, Sara Salehi},
  title = {Thyroxine Treatment of Adult RTHα Patients: Safety, Efficacy, and Metabolomic Changes},
  journal = {Thyroid®},
  year = {2026},
  doi = {10.1177/10507256261460201}
}
Kostenlos starten →